Sheri Laird, MD
Internal Medicine · West Linn, ORNPI 1891731733
Payments from drug & device makers
Across 85 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$307
- AstraZeneca$242
- Biohaven Pharmaceuticals, Inc.$151
- GSK$131
- Biohaven Pharmaceutical Holding Company Ltd.$98
- Merck$97
- plus $555 from 14 others
What the payments were for
- Food & beverage$1,53597%
- Education$453%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 14 | $307 |
| AstraZeneca | 14 | $242 |
| Biohaven Pharmaceuticals, Inc. | 9 | $151 |
| GSK | 9 | $131 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $98 |
| Merck | 6 | $97 |
| Ironshore Pharmaceuticals Inc. | 4 | $74 |
| Sanofi Pasteur Inc. | 3 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $59 |
| IBSA Pharma Inc. | 2 | $59 |
| Therapeuticsmd, Inc. | 3 | $48 |
| Abbott | 2 | $45 |
| Exact Sciences | 2 | $39 |
| Shire North American Group Inc | 2 | $37 |
| Lilly USA, LLC | 2 | $37 |
| Novo Nordisk | 2 | $36 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Seqirus USA Inc | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Circassia Inc. | 1 | $12 |
How this compares
$1,580 in reported general payments places this provider in the 90th percentile of 1,363 internal medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 15 | $2,286 |
| Atorvastatin Calcium | 79 | $1,225 |
| Levothyroxine Sodium | 85 | $1,035 |
| Gabapentin | 45 | $904 |
| Losartan Potassium | 66 | $763 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 25 | $686 |
| Nystatin | 14 | $543 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 19 | $512 |
| Duloxetine Hcl | 20 | $506 |
| Metoprolol Succinate | 28 | $505 |
| Rosuvastatin Calcium | 23 | $499 |
| Omeprazole | 29 | $456 |
| Lisinopril | 43 | $407 |
| Pregabalin | 19 | $405 |
| Mirtazapine | 12 | $380 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in West Linn
- Stephen SpurgeonPortland$8.6M
- Drissana TranSalem$4.8M
- James BergtholdPortland$4.7M
- Stephen FortmannPortland$3.3M
- Maryann ConradPortland$2.7M
- Brian CurtisCorvallis$2.4M
- Jennifer SaultzPortland$1.9M
- Elizabeth LilesHillsboro$1.9M
- Marc UemuraEugene$1.6M
- Michael ChenStayton$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.